SCHEMBL20624604

SCHEMBL20624604

CC(C)Cn1c(NC(=O)CC(C)(O)c2ccccc2)nc2ccc(C(F)(F)F)nc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACSS2 Q9NR19 4/20 0.36
ALDH1A1 P00352 6/20 0.36
LMNA P02545 4/20 0.36
KDM4E B2RXH2 4/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MAPT P10636 2/20 0.36
MEN1 O00255 1/20 0.36
HPGD P15428 1/20 0.36
MAPK1 P28482 1/20 0.36
RECQL P46063 1/20 0.36
KMT2A Q03164 1/20 0.36
HSD17B10 Q99714 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.34
RORC P51449 1/20 0.34
NLRP3 Q96P20 1/20 0.33
TLR7 Q9NYK1 1/20 0.33
POLB P06746 1/20 0.33
OPRK1 P41145 1/20 0.33
S1PR1 P21453 1/20 0.33
CSNK1D P48730 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19277969 1.00 ACSS2 (0.36) ACSS2ALDH1A1LMNAKDM4ESMN1; SMN2
SCHEMBL19277970 0.88 RORC (0.35) ALDH1A1LMNAMEN1KMT2ARORC
SCHEMBL19276091 0.87 ACSS2 (0.38) ACSS2ALDH1A1LMNAKDM4ESMN1; SMN2
SCHEMBL16084176 0.87 CSNK1D (0.40) ALDH1A1LMNASMN1; SMN2MEN1HPGD
SCHEMBL24846139 0.87 ACSS2 (0.37) ACSS2ALDH1A1LMNAKDM4ESMN1; SMN2
SCHEMBL20624606 0.87 ACSS2 (0.37) ACSS2ALDH1A1LMNAKDM4ESMN1; SMN2
SCHEMBL19276095 0.87 ACSS2 (0.37) ACSS2ALDH1A1LMNAKDM4ESMN1; SMN2
SCHEMBL20624126 0.85 ROCK2 (0.39)
SCHEMBL19278279 0.85 ROCK2 (0.39)
SCHEMBL19277819 0.85 ROCK2 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230000831-A1 KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE CHANNEL BIOSCIENCES, LLC 2023-01-05 US disclosed
US-20210130299-A1 KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-05-06 US disclosed
US-10851067-B2 Kv7 channel activators compositions and methods of use KNOPP BIOSCIENCES LLC (US) 2020-12-01 US disclosed
US-20190284142-A1 KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE CHANNEL BIOSCIENCES, LLC 2019-09-19 US disclosed
US-20190002464-A1 IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2019-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190284142-A1 KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE KCNA7, KCNK17, KCNAB1 ACSS2 2521/4885ALDH1A1 3093/4885LMNA 1881/4885
US-20230000831-A1 KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE KCNA7, KCNK17, KCNAB1 ACSS2 2521/4885ALDH1A1 3093/4885LMNA 1881/4885
US-20190002464-A1 IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KCNA7, KCNA2, KCNK17 ACSS2 2525/4885ALDH1A1 1531/4885LMNA 2739/4885
US-10851067-B2 Kv7 channel activators compositions and methods of use KCNA7, KCNK17, KCNAB1 ACSS2 2521/4885ALDH1A1 3093/4885LMNA 1881/4885
US-20210130299-A1 KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE KCNA7, KCNK17, KCNAB1 ACSS2 2521/4885ALDH1A1 3093/4885LMNA 1881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.